Madrigal Pharmaceuticals, Inc. MDGL Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s interest expense?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported interest expense of $7.82M in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s interest expense changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s interest expense increased by 137.2% year-over-year, from $3.3M to $7.82M.
- What does interest expense mean?
- The cost of borrowing money, paid as interest on debt.
- How do you interpret interest expense?
- An increase indicates higher debt levels or rising interest rates, while a decrease suggests debt repayment or refinancing at better terms.
- How does interest expense compare across companies?
- Interest expense is compared to total debt to evaluate the company's cost of borrowing relative to industry peers.